While randomized clinical trials for GLP-1 RAs have shown no benefit when it comes to heart failure (53–56), the HARMONY Outcomes trial suggested a 29% reduction in heart failure hospitalization as a secondary outcome (57); further, in one meta-analysis, there was a 9% reduction in heart failure hospitalization (58). Here, GLP1R is linked to heart failure.